AURA
Price
$6.30
Change
+$0.28 (+4.65%)
Updated
Dec 3 closing price
Capitalization
400.07M
117 days until earnings call
Intraday BUY SELL Signals
NMRA
Price
$2.27
Change
+$0.04 (+1.79%)
Updated
Dec 3 closing price
Capitalization
385.76M
Intraday BUY SELL Signals
Interact to see
Advertisement

AURA vs NMRA

Header iconAURA vs NMRA Comparison
Open Charts AURA vs NMRABanner chart's image
Aura Biosciences
Price$6.30
Change+$0.28 (+4.65%)
Volume$140.92K
Capitalization400.07M
Neumora Therapeutics
Price$2.27
Change+$0.04 (+1.79%)
Volume$1.43M
Capitalization385.76M
AURA vs NMRA Comparison Chart in %
AURA
Daily Signal:
Gain/Loss:
NMRA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AURA vs. NMRA commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a StrongBuy and NMRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (AURA: $6.02 vs. NMRA: $2.23)
Brand notoriety: AURA and NMRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURA: 27% vs. NMRA: 57%
Market capitalization -- AURA: $400.07M vs. NMRA: $385.76M
AURA [@Biotechnology] is valued at $400.07M. NMRA’s [@Biotechnology] market capitalization is $385.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURA’s FA Score shows that 1 FA rating(s) are green whileNMRA’s FA Score has 1 green FA rating(s).

  • AURA’s FA Score: 1 green, 4 red.
  • NMRA’s FA Score: 1 green, 4 red.
According to our system of comparison, NMRA is a better buy in the long-term than AURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AURA’s TA Score shows that 4 TA indicator(s) are bullish while NMRA’s TA Score has 5 bullish TA indicator(s).

  • AURA’s TA Score: 4 bullish, 5 bearish.
  • NMRA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NMRA is a better buy in the short-term than AURA.

Price Growth

AURA (@Biotechnology) experienced а -1.47% price change this week, while NMRA (@Biotechnology) price change was -0.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

AURA is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AURA($400M) and NMRA($386M) have the same market capitalization . AURA YTD gains are higher at: -26.764 vs. NMRA (-78.915). AURA has higher annual earnings (EBITDA): -107.51M vs. NMRA (-264.06M). NMRA has more cash in the bank: 218M vs. AURA (177M). AURA has less debt than NMRA: AURA (18.1M) vs NMRA (20M). AURA (0) and NMRA (0) have equivalent revenues.
AURANMRAAURA / NMRA
Capitalization400M386M104%
EBITDA-107.51M-264.06M41%
Gain YTD-26.764-78.91534%
P/E RatioN/AN/A-
Revenue00-
Total Cash177M218M81%
Total Debt18.1M20M91%
TECHNICAL ANALYSIS
Technical Analysis
AURANMRA
RSI
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
82%
Momentum
ODDS (%)
Bullish Trend 7 days ago
72%
Bearish Trend 7 days ago
77%
MACD
ODDS (%)
Bullish Trend 7 days ago
84%
Bearish Trend 7 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
76%
Bearish Trend 7 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
76%
Bearish Trend 7 days ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 9 days ago
89%
Declines
ODDS (%)
Bearish Trend 15 days ago
84%
Bearish Trend 11 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
75%
Aroon
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AURA
Daily Signal:
Gain/Loss:
NMRA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSDIX18.50N/A
N/A
Fidelity Strategic Dividend & Income
IBALX37.55N/A
N/A
Transamerica Multi-Managed Balanced A
AFCHX17.32N/A
N/A
American Century Focused Intl Gr C
JSJIX17.42N/A
N/A
JHancock Small Cap Dynamic Growth I
ISMVX11.17N/A
N/A
William Blair Small-Mid Cap Value I

AURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AURA has been loosely correlated with NUVL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURA
1D Price
Change %
AURA100%
-3.06%
NUVL - AURA
48%
Loosely correlated
-1.37%
DSGN - AURA
47%
Loosely correlated
+0.11%
RGNX - AURA
46%
Loosely correlated
-3.10%
IDYA - AURA
46%
Loosely correlated
-1.75%
DYN - AURA
46%
Loosely correlated
-2.96%
More

NMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with NGNE. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then NGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NMRA
1D Price
Change %
NMRA100%
-7.64%
NGNE - NMRA
38%
Loosely correlated
-6.01%
ABOS - NMRA
37%
Loosely correlated
-7.11%
AURA - NMRA
36%
Loosely correlated
-3.06%
SNDX - NMRA
35%
Loosely correlated
-1.67%
RCUS - NMRA
34%
Loosely correlated
-2.49%
More